Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective

Fruquintinib is associated with a low budget impact for payers based on proposed thresholds in the US.

Authors

Alemseged Ayele Asfaw (ORCID: https://orcid.org/0000-0002-1014-3510)
Victoria Federico Paly (ORCID: https://orcid.org/0000-0003-3508-1296)
P Khanduri (ORCID: https://orcid.org/0000-0003-2895-4423)
Luis Hernández (ORCID: https://orcid.org/0000-0002-9532-546X)
Shujun Li (ORCID: https://orcid.org/0000-0003-1763-3085)
Denise Zou (ORCID: https://orcid.org/0009-0002-5549-7475)

Institutions

Ithaka Harbors (US)
Takeda (United States) (US)
Takeda (Japan) (JP)

Publication Details

Journal: Journal of Medical Economics
Published: 2024-08-05
DOI: https://doi.org/10.1080/13696998.2024.2389005
Primary Topic: Colorectal Cancer Treatments and Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective

Alemseged Ayele Asfaw, Victoria Federico Paly, P Khanduri, Luis Hernández et al.

Aug 5, 2024

Journal of Medical Economics

Colorectal Cancer Treatments and Studies

article

Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective

Alemseged Ayele Asfaw, Victoria Federico Paly, P Khanduri, Luis Hernández, Shujun Li, Denise Zou

August 5, 2024article en

Abstract

Fruquintinib is associated with a low budget impact for payers based on proposed thresholds in the US.

Journal of Medical EconomicsVol. 27(1)

Ithaka Harbors (US), Takeda (United States) (US), Takeda (Japan) (JP)

Good health and well-being

Openalex Percentile: Top 78%

Colorectal Cancer Treatments and Studies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective — Alemseged Ayele Asfaw, Victoria Federico Paly, et al. · Journal of Medical Economics (2024) | TGRS Research Map | TGRS